Pneumococcal conjugate second or third-dose vaccines (PCVc) in Panama
Panama: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 77.0% in 2025. ▲ Rising
Latest (2025)
77.0%
Change on year
down 9.4%
World rank
124th
of 194 countries
All-time high
97.0%
in 2017
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Panama, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Panama is 77.0%, measured in 2025.
The figure is down 9.4% on the previous year and down 16.3% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Panama peaked at 97.0% in 2017 and was at its lowest, 0.0%, in 2008.
Panama ranks 124th of 194 countries on this measure, in the middle of the range.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Panama, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 48.0% | — |
| 2011 | 63.0% | +31.2% |
| 2012 | 76.0% | +20.6% |
| 2013 | 88.0% | +15.8% |
| 2014 | 91.0% | +3.4% |
| 2015 | 92.0% | +1.1% |
| 2016 | 94.0% | +2.2% |
| 2017 | 97.0% | +3.2% |
| 2018 | 97.0% | +0.0% |
| 2019 | 96.0% | -1.0% |
| 2020 | 74.0% | -22.9% |
| 2021 | 87.0% | +17.6% |
| 2022 | 84.0% | -3.4% |
| 2023 | 77.0% | -8.3% |
| 2024 | 85.0% | +10.4% |
| 2025 | 77.0% | -9.4% |
Panama compared with similar countries
- Panama's 77.0% is below the median for high income countries, which is 91.0%, 85% of the median. (63 countries reporting)
- Panama's 77.0% is below the median for Latin America & Caribbean, which is 82.5%, 93% of the median. (32 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 84.2% | 48.0% | 97.0% | 10 |
| 2020s | 80.7% | 74.0% | 87.0% | 6 |
Countries ranked near Panama
More health data for Panama
- Un projection of annual infant deaths, annual growth rate -1.94 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5994 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,074 deaths per 1,000 people (2090)
- Number of infants who die before age 1 101 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 1 (2025)
- Population ages 00-04, female, annual growth rate -0.2522 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0378 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.3451 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Panama?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Panama was 77.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Panama?
- The highest recorded value was 97.0% in 2017.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Panama?
- The lowest recorded value was 0.0% in 2008.
- How does Panama rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Panama ranks 124th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Panama?
- Over the last ten years it is down 16.3%. The long-run trend across the full record is rising.
- Where does this Panama data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).